3,087 Shares in Ascendis Pharma A/S $ASND Purchased by Rose Capital Advisors LLC

Rose Capital Advisors LLC purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 3,087 shares of the biotechnology company’s stock, valued at approximately $823,000.

Other institutional investors have also added to or reduced their stakes in the company. Sapient Capital LLC bought a new stake in Ascendis Pharma A/S in the 2nd quarter worth approximately $24,581,000. Quantitative Investment Management LLC bought a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at approximately $529,000. Ferguson Wellman Capital Management Inc. bought a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at approximately $693,000. Braun Stacey Associates Inc. boosted its position in shares of Ascendis Pharma A/S by 1.3% during the 2nd quarter. Braun Stacey Associates Inc. now owns 132,682 shares of the biotechnology company’s stock valued at $35,389,000 after acquiring an additional 1,690 shares during the last quarter. Finally, Dearborn Partners LLC purchased a new position in shares of Ascendis Pharma A/S in the second quarter valued at $347,000.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND opened at $270.56 on Friday. The stock’s fifty day moving average is $257.84 and its 200 day moving average is $240.69. Ascendis Pharma A/S has a fifty-two week low of $186.05 and a fifty-two week high of $282.15. The firm has a market capitalization of $16.88 billion, a PE ratio of 20.99 and a beta of 0.35. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The company had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post 5.15 earnings per share for the current year.

Insider Buying and Selling at Ascendis Pharma A/S

In other news, Director Jean-Jacques Bienaimé bought 2,000 shares of the stock in a transaction dated Friday, August 14th. The stock was purchased at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the acquisition, the director owned 2,900 shares of the company’s stock, valued at $714,357. The trade was a 222.22% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 40.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ASND shares. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Stifel Nicolaus lowered their price objective on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Royal Bank Of Canada lifted their price objective on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. Oppenheimer boosted their target price on shares of Ascendis Pharma A/S from $304.00 to $312.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Morgan Stanley decreased their target price on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Buy” and an average price target of $310.05.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.